Researchers predict that without effective exit screening, Ebola-infected travelers will continue to pose a significant risk of international spread. With 2-3 cases predicted to travel abroad every month, countries with limited medical resources may struggle to respond effectively to imported cases.
A study published in The Lancet suggests that controlling Ebola outbreaks at the source in West Africa is the most effective way to prevent international spread. Focusing on exit screening for travelers leaving affected countries can be a more efficient approach than entry screening.
The Journal of Disaster Medicine and Public Health Preparedness has launched a special issue on Ebola, featuring a clinician primer prepared by Dr. Eric Toner and colleagues. The primer covers the history, epidemiology, microbiology, clinical manifestations, biosafety, prevention, treatment, and experimental vaccines of the Ebola virus.
Experts warn conventional US medical centers may struggle to manage Ebola due to lack of preparedness and training. Regional referral centers could help address the shortage of high-level biocontainment patient facilities.
The NIH has granted a license agreement for a candidate Ebola vaccine that also protects against the rabies virus. Studies have shown the vaccines are safe and induce immune responses in monkeys, offering protection against the Zaire strain of Ebola.
The study found that measles death rates were 197 times greater in developing countries than in developed countries, while syphilis death rates were 33-45 times higher. Ebola mortality rates were also significantly higher in developing countries, with 4,447 deaths compared to just two in developed nations.
The Scripps Research Institute team is investigating the deadly Lassa fever virus with a $6.6 million NIH grant. The five-year study aims to understand how the immune system fights off the virus and develops new treatments for the disease. Researchers will analyze cells, chemicals, and genetics of patients to uncover key findings.
A commentary cautions against using experimental Ebola drugs without proper triage to minimize risks. Meanwhile, health economists highlight a major flaw in the FDA's cost-benefit analysis of proposed cigarette labeling regulations. Additionally, a national study reveals that medical residents have varying levels of knowledge on High V...
Researchers analyzed Ebola data to estimate case fatality rates and impact of control measures on epidemic size. They found that swift interventions can halt transmission and prevent outbreaks, with Nigeria's response being a successful example.
The University of Maryland School of Medicine has begun a clinical trial in health care workers in Mali to evaluate a promising experimental Ebola vaccine. The vaccine, developed by the Vaccine Research Center at NIAID, has shown highly protective immune responses in animal model challenge studies.
A new study reports the discovery of a universally conserved drug target for Ebola, which can be used to develop effective anti-Ebola agents against all known species. The researchers have produced a peptide mimic that displays a functionally critical region of the virus, making it suitable for use in high-throughput drug screens.
The Society for Disaster Medicine and Public Health is launching a special issue on Ebola, providing timely expert information to address the virus. The journal aims to translate science into practice, integrating medical and public health perspectives to effectively deal with major events.
A new study analyzing the first outbreak of Ebola in 1976 found that reducing community transmission and changing behavior were crucial to controlling the outbreak. The study suggests that if communities had not changed their behavior, the outbreak could have been much larger, with potentially devastating consequences.
Researchers at Lund University have discovered that viruses can convert their solid DNA to a liquid form, making it easier to infect cells. This temperature-dependent phase transition could lead to the development of new medicines targeting virus DNA, potentially reducing infection capability and spreading.
Australia's lack of preparedness for Ebola is highlighted by experts who call for a national disease control centre to coordinate risk assessments and response plans. The current outbreak in multiple regions of five countries underscores the need for such a centre.
Researchers predict 6,800 new Ebola cases in West Africa by end of month due to increased rate of rise in August. Mass quarantine efforts may have worsened the outbreak by crowding people together in unsanitary conditions.
Researchers create a new tool to study Ebola virus in wildlife using fecal samples, providing insights into the virus' distribution and potentially changing disease understanding. The method detects antibodies against Ebola virus in ape feces, suggesting some apes survive exposure.
Researchers at the University of Warwick found that a mathematical model replicating Ebola outbreaks can no longer predict its scale. The current outbreak is 'out of all proportion' and defies previous patterns.
A team of scientists at UVA has obtained the crystal structure of a key Ebola virus protein, revealing a novel tertiary fold that could lead to insights into viral assembly and antiviral drug design. The study's results may provide a potential target for the development of new treatments for Ebola hemorrhagic fever.
The current Ebola outbreak in West Africa requires a rapid global response to contain the virus, which has already killed nearly 2000 people and may infect up to 20,000. Experts warn that fear, mistrust, and lack of resources are exacerbating the situation.
Penn Medicine bioethicists emphasize the duty to provide humanitarian assistance, global justice, and ethical requirements to combat the Ebola outbreak. The experts also discuss the importance of randomized clinical trials in advancing research and ensuring fair benefits for communities affected by the disease.
Researchers analyzed case counts to find consistent high transmission rates, with Liberia and Sierra Leone reporting one to two new cases for every existing case. The study suggests that controlling the epidemic could be achieved by preventing more than half of secondary transmissions.
Researchers have discovered a novel virus in ball pythons that could be the source of severe respiratory disease, with implications for public health and animal care. The virus, named ball python nidovirus, has been sequenced and found to be similar to toroviruses, which infect mammals and fish.
Researchers have successfully tested a new vaccine regimen that provides rapid protection against Ebola virus in monkeys, with some animals remaining protected for up to 10 months after vaccination. The experimental ChAd3 Ebola vaccine demonstrated strong immune responses in both single-dose and prime-boost regimens.
Researchers found the avian H3N8 flu virus, which killed harbor seals, can spread through respiratory droplets and pose a threat to humans. Human immunity to the virus is lacking, raising concerns about possible person-to-person airborne spread.
A new Comment in The Lancet calls for a Global Health Systems Fund to prevent future infectious disease crises and strengthen health infrastructure. The proposed fund would address human resource shortages and fragile health systems that contributed to the devastating Ebola outbreak.
Researchers have identified a potential therapeutic approach against Ebola virus infection by targeting cellular proteins critical for the virus's functions. Oubain, a drug previously used to treat heart disease, has been shown to reduce virus replication in infected cells.
Researchers at the Washington University School of Medicine identified how Ebola dodges antiviral defenses by hijacking a host protein's ability to carry an important immune signal. This finding could lead to new therapies targeting the virus's deadliness.
A blend of three monoclonal antibodies has been shown to protect monkeys against a lethal dose of Ebola virus for up to 5 days after infection. This treatment, ZMAPP, was found to be effective in a study published in Nature.
A new Ebola treatment has shown promise against the Sudan strain of the virus in mice, using synthetic antibodies designed to target a key molecule on the surface of the virus. The treatment is not effective against the Zaire ebolavirus, which is currently devastating West Africa.
A candidate Ebola vaccine is being tested on healthy volunteers in the UK, The Gambia, and Mali as part of an international collaboration. The phase 1 trials aim to ensure the vaccine's safety and immunogenicity before deployment to high-risk populations.
Researchers sequenced over 99 Ebola virus genomes from 78 patients in Sierra Leone, finding more than 300 genetic changes that make the 2014 Ebola virus distinct from previous outbreaks. The data provides insights into the outbreak's origin, transmission, and potential targets for diagnostics, vaccines, and therapies.
The National Institute of Allergy and Infectious Diseases (NIAID) has launched an initial human safety study for an Ebola vaccine candidate. The trial is the first in a series of Phase 1 clinical trials that will examine the investigational NIAID/GSK Ebola vaccine, which is designed to induce an immune response in healthy adults.
Respiratory infection control measures for Ebola patients are unnecessary and may contribute to public panic, according to a new letter published in The Lancet. Excessive precautions could reinforce the view that some lives are more valuable than others, exacerbating the spread of infection.
Researchers develop a potential therapy for Sudan ebolavirus, showing promising results in laboratory tests and mouse models. The humanized antibody has been identified as an immunotherapeutic candidate to treat SUDV infection.
Experts say 14th century Venice's response to the plague holds lessons on how to mitigate the consequences of today's emerging threats. The city's use of resilience management, including physical movement management and quarantine measures, can inform strategies for dealing with highly infectious diseases like Ebola.
A study found that many hospitals in low- and middle-income countries have insufficient stocks of sterile gloves, eyewear, and other protective equipment. This is particularly concerning in the context of the current Ebola outbreak.
Researchers found that TIM-family proteins can block the release of HIV and Ebola viruses by attaching to lipids on the surface of viral particles. This discovery provides a potential approach to slow virus production and replication.
A commentary published in Annals of Internal Medicine highlights two factors contributing to Ebola infection among healthcare workers: insufficient supply of personal protective equipment and inadequate donning/doffing procedures. To prevent transmission, the authors recommend a structured process for gear removal.
The American College of Chest Physicians has released a consensus statement providing evidence-informed suggestions for preparing and managing the critically ill and injured during large-scale disasters and pandemics. The document aims to guide ethical decision-making, coordination of care, resource conservation, and research in crises.
The Lancet emphasizes the need for fair distribution of experimental Ebola drugs and rigorous testing in clinical trials. Bioethicists recommend prioritizing containment of the epidemic and strengthening health systems over treatment with potentially ineffective interventions.
Ebola treatment expert Jesse L. Goodman advocates for expedited studies of promising treatments while prioritizing patient safety. He suggests completing basic safety studies in healthy humans before treating sick patients.
Two commentaries in Annals of Internal Medicine emphasize the need for immediate Ebola vaccine deployment and cautious approach to containment plans. The authors argue that safety risks from vaccines are negligible compared to healthcare worker risks, while excessive measures can foster mistrust and increase risk.
Research reveals Ebola's profound effects on gorilla populations, including changes in reproduction, immigration, and social dynamics. Long-term monitoring is necessary to understand disease impacts on wildlife.
The article highlights the importance of recognizing Ebola virus infection and isolating patients in hospitals worldwide. Despite concerns about transmission, experts argue that developed countries' effective hospital infection control practices minimize the risk of further spread.
Two American missionaries who contracted Ebola virus in West Africa deserve special treatment for their selfless act of caring for infected patients. The author argues that limiting experimental treatment to these two patients is necessary due to the ethical concerns of exploiting vulnerable individuals during a public health outbreak.
A recent study published in Clinical Microbiology and Infection warns of the high risk of Chikungunya virus spread in the Americas and Europe due to mosquito-borne transmission. The disease can cause severe symptoms, including fever, joint pain, and muscle aches, with no available treatment.
A study published in Cell Host & Microbe reveals how the Ebola virus blocks the body's first line of defense against infection. By targeting a specific protein called eVP24, the virus cripples the immune system's ability to respond effectively, allowing it to mass-produce itself and trigger a deadly response.
The Ebola virus outbreak in West Africa has claimed over 1,000 lives, with healthcare professionals facing new challenges in capital cities and Nigeria. Dr. Fauci emphasizes the need for sound public health practices, community engagement, and international assistance to defeat the epidemic.
Researchers have discovered how Ebola blocks and disables the body's natural immune response. The protein VP24 disrupts a crucial early step in the virus's path to causing deadly disease. Understanding this mechanism could lead to new treatments for the deadly virus.
A commentary published in Annals of Internal Medicine reveals the history of 'miraculous' Ebola virus serotherapy, inspired by 19th century discoveries. Additionally, two systematic reviews address challenges of interpreting troponin levels in patients with chronic kidney disease.
The University of Texas Medical Branch at Galveston has received over $6 million to develop experimental drugs against Ebola and Marburg viruses. The research aims to understand how these viruses disable the immune system and create effective treatments for patients infected with filoviruses.
Researchers found that cells are constantly fighting herpes virus, even in dormant phase, leading to potential new treatments. The study used genetically modified cells and viruses to measure virus activity, revealing varying levels of infection across different cells.
Scientists discovered a new pathway the dengue virus takes to suppress the human immune system, deepening understanding of the virus and its potential for more effective treatments. The study reveals how sfRNA interacts with proteins in the cell to evade antiviral defenses.
Researchers analyzed clinical samples from suspected Lassa fever cases in Sierra Leone and found nearly 9% tested positive for Ebola virus. The study demonstrates that Ebola has been circulating in the region since at least 2006.
Researchers found that Wolbachia-infected mosquitoes are more likely to transmit West Nile virus, despite initial expectations that it would block infection. The study suggests that releasing Wolbachia-infected mosquitoes into the wild may increase the risk of West Nile virus transmission.
Researchers in Sierra Leone call for enhanced access to diagnostic technologies, healthcare resources, and disease surveillance systems. They also highlight the need for reliable personal protective equipment and effective communication to combat misinformation and improve compliance with prevention measures.
Researchers found that combining low doses of bortezomib with an oncolytic virus significantly improves the ability to kill cancer cells. The combination treatment suppressed tumor growth by 92% in a glioma model and improved survival rates, offering a novel therapeutic strategy for solid tumors.
A team of researchers has identified eight genes from influenza viruses isolated from wild ducks that possess genetic similarities to the 1918 pandemic flu virus. The new study shows that these gene pools have the potential to cause a severe pandemic in the future if combined with other viral components.
Researchers have discovered a bird flu virus with pandemic potential, closely related to the 1918 Spanish flu. The virus, composed of eight gene segments, can cause flu-like symptoms in ferrets and has the potential to spread efficiently among humans if it acquires key mutations.